| Date | Title | Description |
| 13.08.2024 | Myrobalan Therapeutics: Additional $9 Million Raised And Grant Bogle Joins Board | Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system (CNS) conditions, announced the appointment of Grant C. Bog... |
| 19.12.2019 | FDA panel recommends approval of Epizyme drug for rare cancer | Shares of Epizyme rose 35.6% on the Nasdaq Wednesday following the news, before leveling off and by Thursday afternoon trading at around 8% above their Wednesday closing price.
“We are incredibly pleased by ODAC’s unanimous support for the ... |
| 05.11.2019 | Epizyme Raises Up to $270M in Funding | Epizyme, Inc. (Nasdaq: EPZM), a Cambridge, Mass.-based late-stage biopharmaceutical company developing novel epigenetic therapies, closed funding agreements that, in aggregate, could bring in up to $270m in capital.
The backers were Royalty... |
| 25.07.2019 | FDA to make decision on Epizyme drug for rare cancer by January 2020 | Epizyme’s shares fell nearly 11 percent on the Nasdaq when markets opened Thursday, but quickly recovered their value and are currently up nearly 1 percent from their Wednesday closing price.
Data from the 62 patients were shown in an oral ... |
| 07.02.2017 | Epizyme Elects Kevin Conroy to its Board of Directors | Cambridge, MA — Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy, chairman and chief executive officer of... |
| 06.05.2016 | Epizyme Appoints Matthew Ros as Chief Operating Officer | Cambridge, MA — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its senior leadership team with the addition of Matthe... |
| 05.05.2016 | Epizyme Announces FDA Acceptance of IND Application for Tazemetostat in Mesothelioma | Cambridge, MA — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the U.S. Food and Drug Administration has accepted the company’s Inves... |
| 08.02.2016 | Epizyme’s Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors | Cambridge, MA — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that the United States Food and Drug Administration (FDA) has granted orpha... |
| 09.07.2015 | Epizyme Announces Extension of Celgene Research Collaboration | Cambridge, MA — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced that it has amended and restated its agreement with Celgene Corporation to ext... |
| 09.07.2015 | Epizyme Doses First Patient in Phase 2 Study for Tazemetostat (EPZ-6438) in Non-Hodgkin Lymphoma | Cambridge, MA — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that it has dosed the first patient in the phase 2 trial of its lead clinical ... |
| 20.06.2015 | Epizyme Announces Additional Positive Data from Ongoing Phase 1 Study of Tazemetostat (EPZ-6438) | Lugano, Switzerland — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today reported results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a f... |
| 21.04.2015 | Epizyme Presents Preclinical Research Providing Deeper Understanding of Multiple Cancer Targets | Philadelphia, PA — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the presentation of data on two epigenetic targets in its pioneering therap... |
| 18.03.2015 | Epizyme Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 6,000,000 shares of ... |
| 12.03.2015 | Epizyme Reacquires Global Rights from Eisai for First-in-Class EZH2 Inhibitor EPZ-6438 | CAMBRIDGE, Mass., Mar 12, 2015 (BUSINESS WIRE) — Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that it has reacquired global rights to its EZH2 program,... |
| 19.11.2014 | Epizyme Announces Phase 1 Dose Escalation Data for EZH2 Inhibitor EPZ-6438(E7438) | Barcelona, Spain – Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the results from the Phase 1 dose escala... |
| 12.08.2014 | Epizyme Presents Pre-Clinical Data and Early Clinical Observations at ASH Meeting on Lymphoma Biology | Colorado Springs, CO — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical obser... |
| 22.04.2014 | Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments | Cambridge, MA — Epizyme, Inc. EPZM +9.15% , a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate milest... |
| 30.10.2013 | Which venture capital firm’s healthcare investment picks secured the most IPOs? | I won’t get into Aratana Therapeutics (Nasdaq: PETX) because the biopharmaceutical company develops treatments for animals.
Acceleron Pharma: (Nasdaq: XLRN) raised $96.7 million after it priced at the high end of its share price range. The ... |
| 08.10.2013 | Bay City Capital Names Ashley Ledbetter Dombkowski, PhD, Managing Director | San Francisco, CA — Bay City Capital, a leading venture capital firm focused on early-stage to growth equity investments in the life sciences, today announced Ashley Dombkowski, Ph.D. joined as Managing Director.
“Drug discovery and develo... |
| 13.05.2013 | Bay City Capital Expands Team with the Addition of David Beier, JD | San Francisco, CA — Bay City Capital, a leading venture capital firm focused on early-stage to growth equity investments in the life sciences, today announced the addition of David Beier, JD as Managing Director. David served as a senior of... |
| 26.04.2013 | Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering | April 26, 2013
Cambridge, MA — Epizyme, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common st... |
| 26.04.2012 | Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration | Celgene also has a phase 3 trial under way that is using the Abraxane in the treatment of metastatic pancreatic cancer with data expected in the second half of 2012 or the first half of 2013. It has at least six late-stage clinical trials u... |
| 10.03.2011 | Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme | March 10, 2011
Cambridge, MA — Epizyme, Inc. announced today a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma... |
| 08.12.2009 | Epizyme Closes $40M Series B Financing adding NEA to Investor Syndicate | Epizyme, Inc., a Cambridge, MA-based biopharmaceutical company that creates innovative drugs for major diseases based on discoveries emerging from the field of epigenetics, announced the participation of New Enterprise Associates (NEA) in i... |
| 07.10.2009 | USA, Epizyme Closes $32M Series B Financing | Cambridge, MA-based Epizyme, Inc., a biopharmaceutical company founded in 2007 to create innovative drugs for major diseases based on new discoveries emerging from the field of epigenetics, closed a $32m Series B financing led by new invest... |
| - | Epizyme to Host Strategic Vision Call on March 2, 2021 | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2021--
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it will host a call to disc... |
| - | Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration | Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies.
Since the drug is for an unmet need, the company ... |
| - | Which venture capital firm’s healthcare investment picks secured the most IPOs? | Biotechnology and healthcare companies have been going public at a good clip this year, at a rate that overshadows the past few years. But initial public offerings are not what they used to be. Although they used to mark an exit for a compa... |
| - | FDA panel recommends approval of Epizyme drug for rare cancer | A drug for treating a rare form of connective-tissue cancer looks likely to win Food and Drug Administration approval after a unanimous positive vote by a panel of experts.
The FDA’s Oncologic Drugs Advisory Committee voted 11-0 to recommen... |
| - | FDA to make decision on Epizyme drug for rare cancer by January 2020 | The Food and Drug Administration will review an investigational drug for a rare type of cancer that affects soft tissues under the skin.
Cambridge, Massachusetts-based Epizyme said Thursday that the agency had accepted its application for a... |
| - | Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 2, 2021--
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today outlining the Company’s ... |
